Sun Pharmaceutical Industries profit and loss

Latest FY26

Revenue: ₹58,462cr+11.2% on FY25
EBITDA: ₹17,731cr+16.1% on FY25
Net profit: ₹11,509cr+5.0% on FY25
EPS: ₹47.80+4.8% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	59,911	58,462	52,578	48,497	43,886	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	2,231	1,972	1,965	1,354	635
	62,141	60,434	54,543	49,851	44,520
	7,644	7,389	6,449	6,904	7,778
	3,783	3,812	4,148	3,466	3,572
	265	343	150	292	−687
	11,844	11,419	9,973	9,429	8,296
	364	339	231	238	172
	2,976	2,938	2,575	2,557	2,529
	18,527	17,768	16,586	15,382	13,281
	45,403	44,007	40,114	38,269	34,940
	17,847	17,731	15,272	13,023	11,647
	14,871	14,794	12,696	10,466	9,117
Profit
	16,738	16,426	14,430	11,582	9,580
	−694	−1,307	−678	−494	−171
	16,045	15,119	13,752	11,088	9,408
	3,872	3,554	2,772	1,439	848
	3,872	3,554	2,772	1,439	848
	−55.7	−55.9	−15.4	−38.4	−47.9
	12,117	11,509	10,965	9,610	8,513
	12,173	11,565	10,980	9,648	8,561
	5,208	3,827	912	1,142	2,257
	17,325	15,335	11,877	10,752	10,770
	12,096	11,479	10,929	9,576	8,474
	21.4	29.2	35.7	33.7	39.4
Per share
	₹50.40	₹47.80	₹45.60	₹39.90	₹35.30
	₹50.40	₹47.80	₹45.60	₹39.90	₹35.30
Other comprehensive income — detail
	5,208	3,827	912	1,142	2,257
	1,828	303	−45.1	735	98.9
	276	113	−11.6	—	—
	—	—	—	86.1	11.8
	3,606	3,564	945	503	2,163
	−50.8	−72.2	−0.8	—	—
	—	—	—	9.1	−6.2
	17,294	15,281	11,839	10,618	10,503
	32.0	54.3	38.3	134	266
Per share — as-filed variants
	₹50.40	₹47.80	₹45.60	₹39.90	₹35.30
	₹50.40	₹47.80	₹45.60	₹39.90	₹35.30
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	48,218	46,918	41,831	37,834	33,224
	80.5%	80.3%	79.6%	78.0%	75.7%
Adjusted (ex-exceptional items) — derived
	16,738	16,426	14,430	11,582	9,580
	−694	−1,307	−678	−494	−171
	12,643	12,509	11,506	10,040	8,669
	₹52.59	₹51.95	₹47.85	₹41.69	₹35.95

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUNPHARMA₹1,757.50

Sun Pharmaceutical Industries Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersCIPLA DRREDDY LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹4.22L Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	43,885.7	48,496.9	52,578.4	58,462.0	59,910.5
Other Income	634.5	1,354.2	1,965.0	1,971.7	2,230.9
Total Income	44,520.2	49,851.0	54,543.5	60,433.8	62,141.4
Expenses
+ Cost of Materials Consumed	7,777.6	6,904.3	6,449.1	7,389.0	7,643.7
+ Purchases of Stock-in-Trade	3,571.5	3,466.2	4,148.0	3,811.5	3,783.1
+ Changes in Inventories	-686.9	292.1	150.3	343.1	265.3
+ Employee Benefit Expense	8,296.0	9,429.1	9,973.1	11,418.9	11,844.4
+ Finance Costs	172.0	238.5	231.4	338.9	363.8
+ Depreciation & Amortisation	2,529.4	2,556.6	2,575.4	2,937.9	2,976.0
+ Other Expenses	13,280.7	15,382.1	16,586.3	17,768.1	18,526.6
Total Expenses	34,940.3	38,268.8	40,113.5	44,007.4	45,402.9
EBITDA	11,646.8	13,023.1	15,271.7	17,731.4	17,847.4
EBIT	9,117.4	10,466.5	12,696.3	14,793.6	14,871.4
Profit
PBT before Exceptional Items	9,579.9	11,582.2	14,430.0	16,426.4	16,738.5
+ Exceptional Items	-171.5	-494.3	-677.9	-1,307.5	-693.6
Pretax Income	9,408.4	11,087.9	13,752.1	15,118.9	16,044.9
+ Current Tax	847.6	1,439.5	2,772.0	3,554.4	3,872.2
Tax Expense	847.6	1,439.5	2,772.0	3,554.4	3,872.2
+ Share of Associates & JVs	-47.9	-38.4	-15.4	-55.9	-55.7
Net Income	8,512.9	9,610.0	10,964.8	11,508.7	12,117.0
+ Net Income — Continuing Ops	8,560.8	9,648.4	10,980.1	11,564.5	12,172.7
+ Other Comprehensive Income	2,256.6	1,142.1	912.4	3,826.7	5,208.5
Total Comprehensive Income	10,769.5	10,752.2	11,877.2	15,335.4	17,325.5
Net Income to Common	8,473.6	9,576.4	10,929.0	11,479.4	12,095.6
Minority Interest	39.4	33.7	35.7	29.2	21.4
Per Share
Basic EPS	35.30	39.90	45.60	47.80	50.40
Diluted EPS	35.30	39.90	45.60	47.80	50.40
Other Comprehensive Income — detail
+ Other Comprehensive Income	2,256.6	1,142.1	912.4	3,826.7	5,208.5
+ Items NOT to be Reclassified to P&L	98.9	734.7	-45.1	302.9	1,827.7
+ Tax on Items NOT to be Reclassified	—	—	-11.6	112.8	275.6
+ Tax on Items NOT to be Reclassified — alt tag	11.8	86.1	—	—	—
+ Items to be Reclassified to P&L	2,163.2	502.7	945.2	3,564.4	3,605.6
+ Tax on Items to be Reclassified	—	—	-0.8	-72.2	-50.8
+ Tax on Items to be Reclassified — alt tag	-6.2	9.1	—	—	—
Comprehensive Income — Owners of Parent	10,503.5	10,617.7	11,838.9	15,281.1	17,293.5
Comprehensive Income — Non-controlling Interests	266.1	134.5	38.3	54.3	32.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	35.30	39.90	45.60	47.80	50.40
Diluted EPS — Continuing Operations	35.30	39.90	45.60	47.80	50.40
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	33,223.5	37,834.2	41,831.1	46,918.4	48,218.4
Gross Margin %	75.70	78.01	79.56	80.25	80.48
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	9,579.9	11,582.2	14,430.0	16,426.4	16,738.5
− Exceptional Items (reconciliation)	-171.5	-494.3	-677.9	-1,307.5	-693.6
Net Income Adj (tax-effected)	8,668.9	10,040.2	11,506.0	12,508.7	12,643.2
EPS Adj	35.95	41.69	47.85	51.95	52.59
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	—	1.00	1.00
Paid Up Equity Capital	239.9	239.9	239.9	239.9	239.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 199%.